Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06826001

Various Procedural Treatment Options for Androgenetic Alopecia

Androgenetic alopecia (AGA)is the most common form of alopecia. It predominantly affects males, but there has been a significant surge in female preponderance too, over the last decade Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years so in this study we are going to compare efficacy of topical minoxidil versus topical finasteride in treatment of androgenetic alopecia

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

20 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Sheikh zayed Medical College and Hospital, Rahim Yar Khan, Punjab 644200

Rahim Yar Khan, Punjab Province, 644200, Pakistan

Location contact

Sheikh zayed Medical college rahim yar khan punjab

CONTACT

[email protected]

+92689230168

About this study

Androgenetic alopecia (AGA)is considered to be a very common form of alopecia. Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth The clinical efficacy of oral finasteride for treating AGA is well established. Although oral finasteride is generally well tolerated Topical finasteride is a medication that is used to treat hair loss in men and women. It is a topical version of the oral medication finasteride, which works by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to hair loss. Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years.

OBJECTIVE "To compare the efficacy of topical finasteride vs topical minoxidil in the treatment of androgenetic alopecia in tertiary care hospital"

DATA COLLECTION:

Data will be collected on prescribed proforma which is attached, at Dermatology OPD, Sheikh Zayed Hospital, Rahim Yar Khan. Patient will be selected on basis of inclusion & exclusion criteria. Informed consent will be taken from selected patients before data collection. Study will include 190 patients which will be divided into 2 groups A & B, 95 in each group. Group A will receive topical finasteride spray 0.25% twice daily for 12 weeks. Group B will receive topical 5% minoxidil twice daily for 12 weeks Patient will be followed at the end of 12 weeks therapy.

DATA ANALYSIS:

Data will be analyzed by SPSS (Statistical Package for the Social Sciences) v25.0.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 20-50 years
  • Gender: Male
  • ANDROGENETIC ALOPECIA with AGA stage 2-6 Norwood-Hamilton -classification
  • Patients not taking any treatment in last 1 month

Exclusion criteria

  • Abrasion or abnormalities to the scalp
  • Hair transplant
  • Hypersensitivity
  • Recent history of local infections of the head
  • History of relevant significant disease active seborrheic dermatitis
  • Concurrent use of :
  • corticosteroids
  • anabolic steroids or over-the-counter 'hair restorers'
  • use of drugs with anti-androgenic properties within 6 months light or laser treatment of the scalp within the last 3 months.

Treatment and study plan

topical finasteride

Drug

Group A will receive topical finesteride spray 0.25% twice daily for 12 weeks

Topical minoxidil

Drug

Group B will receive topical 5% minoxidal twice daily for 12 weeks

Primary outcomes

  1. COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA

    Time frame: Clinical assessment for efficacy will be done monthly for 6 months

    The final efficacy will be divided into following groups on the basis of Norwood-Hamilton scale from the baseline :1.Excellent efficacy: It is defined as greater than two scale change in hair density as measured from baseline . 2. moderate efficacy : It is defined as one to two scale change in hair density as measured from baseline. Percentage increase in hair density as clinically measured by the surface area from the baseline. 3.Non efficacious: It is defined as less than one scale change in hair density as measured clinically from baseline.

Study contacts

Contact information is provided by the study sponsor or research team.

Farah Humera, post graduate resident derma

CONTACT

[email protected]

+923328334251

Sponsors and collaborators

Lead sponsor

Sheikh Zayed Medical College

Other Gov

Registry information

Official study title

COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 13, 2025
Registry last updated
Feb 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.